The FINEARTS-HF trial demonstrated that finerenone, a third-generation nonsteroidal mineralocorticoid receptor antagonist, is effective in reducing heart failure events and cardiovascular deaths in patients with heart failure and mildly reduced or preserved ejection fraction. The trial results showed a 16% reduction in worsening heart failure events with finerenone compared to placebo, with consistent benefits across various subgroups. While concerns about hyperkalemia were noted, the trial showed a low rate of severe hyperkalemia. The results suggest that MRAs like finerenone may be a valuable addition to the treatment of this patient population, alongside existing therapies like SGLT2 inhibitors.
Source link
Finerenone Benefits Heart Failure With Preserved EF
